Dacomitinib Beats Gefitinib for EGFR+ NSCLC [News in Brief]

The second-generation EGFR inhibitor extended progression-free survival, but proved more toxic.

from Cancer via ola Kala on Inoreader http://ift.tt/2shwCeO
via IFTTT